<p>Guardant Health（纳斯达克股票代码：GH - 获取免费报告）于周四发布了季度财报。该公司报告本季度每股收益为（$0.45），超出分析师一致预期的（$0.47）$0.02，FiscalAI 报道。该公司本季度的收入为 3.0167 亿美元，而分析师预期为 2.7915 亿美元。与去年同期相比，该公司的季度收入增长了 48.3%。在去年同期，该公司每股收益为（$0.49）。</p>
<p>获取 <strong>Guardant Health</strong> 的提醒：</p>
<ul>
<li>4 只医疗保健股票大幅上涨——还有更多上涨空间</li>
</ul>
<p>以下是 Guardant Health 电话会议的关键要点：</p>
<ul>
<li><strong>第一季度超预期，全年指引上调</strong> — Guardant 第一季度收入为 <strong>3.02 亿美元</strong>（同比增长 48%），超过 <strong>10 亿美元</strong> 的过去 12 个月收入，并将 2026 年指引上调至 <strong>13 亿–13.2 亿美元</strong>，显示出持续的收入增长势头。</li>
<li><strong>Shield 筛查势头和利润率扩张</strong> — Shield 在第一季度产生了 <strong>4200 万美元</strong> 的收入，进行了约 <strong>44,000</strong> 次测试，遵循率超过 90%，全国范围内的 Quest 分销，新批准的 2 管 FDA 套件，与 Manulife 的亚洲推广，以及筛查毛利率从 18% 提升至 56%；2026 年 Shield 指引为 <strong>1.86 亿–1.98 亿美元</strong>（约 23 万–24.5 万次测试）。</li>
<li><strong>肿瘤产品和人工智能平台的吸引力</strong> — 肿瘤收入为 <strong>2.05 亿美元</strong>（增长 36%）；Guardant360 液体检测量增长 30%，Guardant360 组织检测在全转录组升级后加速，Reveal 检测量超过 100%，InfinityAI/SmartApps 推动更深层次的采用；Guardant360 液体仍在 FDA 审查中。</li>
<li><strong>生物制药/数据合作和 CDx 势头</strong> — 生物制药和数据收入为 <strong>5300 万美元</strong>（增长 17%），Guardant 目前支持 26 个地区的 CDx 批准，战略交易（例如，默克、Nuvalent）以及 InfinityAI 真实世界证据正在加强长期商业管道。</li>
<li><strong>运营支出增加和持续现金消耗</strong> — 非 GAAP 运营费用增长 34% 至 <strong>2.68 亿美元</strong>（销售和市场增长），调整后的 EBITDA 亏损保持在 <strong>5900 万美元</strong>，第一季度自由现金流消耗为 <strong>7100 万美元</strong>，全年自由现金流消耗指引为 <strong>1.85 亿–1.95 亿美元</strong>；公司拥有约 <strong>12 亿美元</strong> 现金，但仍在大力再投资，这可能会对短期盈利能力造成压力。</li>
</ul>
<h2>Guardant Health 股票上涨 0.0%</h2>
<p>周四交易时段，纳斯达克：GH 股票上涨 $0.01，达到 $92.26。该股票交易量为 2,389,102 股，而其平均交易量为 2,172,853 股。该公司的市值为 122.3 亿美元，市盈率为-27.87，贝塔值为 1.48。该公司 50 日简单移动平均为$88.93，200 日简单移动平均为$96.92。Guardant Health 的 52 周低点为$36.36，52 周高点为$120.74。</p>
<h2>Guardant Health 的内部交易</h2>
<ul>
<li>解读颠覆：凯西·伍德最新投资策略</li>
</ul>
<p>在其他 Guardant Health 的新闻中，董事穆萨·塔里克于 3 月 18 日（星期三）出售了 348 股公司股票。股票以平均价格$88.09 出售，总交易额为$30,655.32。交易完成后，该董事在公司持有 8,394 股，价值$739,427.46。此次交易使其持股减少了 3.98%。该交易已在提交给证券交易委员会的文件中披露，相关文件可在此链接查看。此外，内部人士特里林·J·门罗于 4 月 6 日（星期一）出售了 3,832 股股票。股票以平均价格$92.68 出售，总交易额为$355,149.76。出售后，该内部人士直接持有公司 20,990 股，价值$1,945,353.20。此次交易使其持股减少了 15.44%。该销售的 SEC 文件提供了更多信息。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去 90 天内，内部人士共出售了价值$775,767 的 8,596 股公司股票。内部人士持有公司 6.10% 的股份。</p>
<h2>机构投资者对 Guardant Health 的看法</h2>
<p>机构投资者最近调整了对该公司的持股。Parallel Advisors LLC 在第四季度将其在 Guardant Health 的持股增加了 164.7%。Parallel Advisors LLC 现在拥有 352 股公司股票，价值$36,000，在此期间又增持了 219 股。EFG International AG 在第四季度获得了 Guardant Health 的新股份，价值约$41,000。Kestra Advisory Services LLC 在第四季度获得了 Guardant Health 的新股份，价值约$56,000。意大利联合银行控股公司在第四季度购买了 Guardant Health 的新股份，价值约$60,000。最后，丹麦银行在第三季度获得了 Guardant Health 的新股份，价值约$62,000。机构投资者持有公司 92.60% 的股份。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>3 只快速增长的股票，分析师预计价格将翻倍</li>
</ul>
<p>最近，一些分析师对该公司发布了报告。摩根大通将 Guardant Health 的目标价格从 120.00 美元上调至 130.00 美元，并在 2 月 20 日的研究报告中给予该股票 “超配” 评级。Stifel Nicolaus 将 Guardant Health 的目标价格从 120.00 美元上调至 130.00 美元，并在 2 月 20 日的研究报告中给予该公司 “买入” 评级。花旗集团将 Guardant Health 的目标价格从 135.00 美元上调至 150.00 美元，并在 2 月 20 日的报告中给予该股票 “买入” 评级。Raymond James Financial 重申了 “跑赢大盘” 评级，并在 2 月 23 日的研究报告中对 Guardant Health 的股票设定了 129.00 美元的目标价格。最后，TD Cowen 将 Guardant Health 的股票目标价格从 130.00 美元上调至 135.00 美元，并在 2 月 20 日的研究报告中给予该股票 “买入” 评级。十九位研究分析师对该股票给予了 “买入” 评级，一位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 128.63 美元。</p>
<p><strong>阅读我们关于 Guardant Health 的最新研究报告</strong></p>
<h2>关于 Guardant Health</h2>
<p>(获取免费报告)</p>
<p>Guardant Health, Inc 是一家专注于血液癌症诊断的精准肿瘤学公司。公司成立于 2012 年，总部位于加利福尼亚州红木城，开发非侵入性测试，利用循环肿瘤 DNA (ctDNA) 来分析实体肿瘤患者的基因组变化。Guardant Health 的使命是通过向全球临床医生、制药合作伙伴和研究人员提供可操作的数据，推动癌症护理的发展。</p>
<p>该公司的旗舰产品 Guardant360 是一种下一代测序 (NGS) 检测，旨在检测 70 多种与癌症相关的基因中的突变、拷贝数变异和特定融合。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比 Guardant Health 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Guardant Health 吗？</h2>
<p>在考虑 Guardant Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Guardant Health 并不在名单上。</p>
<p>虽然 Guardant Health 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>在这里查看这五只股票</p>

生物科技 ETF - VanEck Vectors

基因免疫&健康关怀 ETF - iShares

<p>Guardant Health（纳斯达克代码：GH）报告的季度收益为每股亏损 0.45 美元，超出预期的每股亏损 0.47 美元，超出幅度为 0.02 美元。收入达到 3.0167 亿美元，超过 2791.5 万美元的预测，同比增长 48.3%。该公司将 2026 年的收入指引上调至 13 亿至 13.2 亿美元，显示出强劲的增长。尽管运营费用增加了 34%，自由现金流净亏损为 7100 万美元，Guardant 仍保持 12 亿美元的现金。该股票交易价格为 92.26 美元，市值为 122.3 亿美元。内部交易显示董事近期有出售股票的行为，机构投资者则增加了持股比例</p>

<p>Guardant Health (NASDAQ:GH - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.47) by $0.02, FiscalAI reports. The firm had revenue of $301.67 million during the quarter, compared to analyst estimates of $279.15 million. The business's quarterly revenue was up 48.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.49) EPS.</p>
<div class="lb-trans"><p>Guardant Health（纳斯达克股票代码：GH - 获取免费报告）于周四发布了季度财报。该公司报告本季度每股收益为（$0.45），超出分析师一致预期的（$0.47）$0.02，FiscalAI 报道。该公司本季度的收入为 3.0167 亿美元，而分析师预期为 2.7915 亿美元。与去年同期相比，该公司的季度收入增长了 48.3%。在去年同期，该公司每股收益为（$0.49）。</p>
</div><p>Get <strong>Guardant Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Guardant Health</strong> 的提醒：</p>
</div><ul>
<li>4 Healthcare Stocks With Massive Gains—and More to Come</li>
</ul>
<div class="lb-trans"><ul>
<li>4 只医疗保健股票大幅上涨——还有更多上涨空间</li>
</ul>
</div><p>Here are the key takeaways from Guardant Health's conference call:</p>
<div class="lb-trans"><p>以下是 Guardant Health 电话会议的关键要点：</p>
</div><ul>
<li><strong>Q1 beat and higher full‑year guide</strong> — Guardant reported <strong>$302M</strong> in Q1 revenue (+48% YoY), surpassed <strong>$1B</strong> TTM revenue, and raised 2026 guidance to <strong>$1.30B–$1.32B</strong>, signaling sustained top‑line momentum.</li>
<li><strong>Shield screening momentum and margin expansion</strong> — Shield generated <strong>$42M</strong> on ~ <strong>44k</strong> tests in Q1, with &gt;90% adherence, nationwide Quest distribution, a new 2‑tube FDA kit approval, Asia rollout with Manulife, and screening gross margin improvement from 18% to 56%; 2026 Shield guidance is <strong>$186M–$198M</strong> (~230k–245k tests).</li>
<li><strong>Oncology product and AI platform traction</strong> — Oncology revenue was <strong>$205M</strong> (+36%); Guardant360 Liquid volumes +30%, Guardant360 Tissue accelerating after whole‑transcriptome upgrade, and Reveal volumes &gt;100% as InfinityAI/SmartApps drive deeper adoption; Guardant360 Liquid remains in FDA review.</li>
<li><strong>Biopharma/data partnerships and CDx momentum</strong> — Biopharma &amp; data revenue was <strong>$53M</strong> (+17%), Guardant now supports 26 CDx approvals across regions, and strategic deals (e.g., Merck, Nuvalent) plus InfinityAI real‑world evidence are strengthening long‑term commercial pipelines.</li>
<li><strong>Higher operating spend and ongoing cash burn</strong> — Non‑GAAP operating expenses rose 34% to <strong>$268M</strong> (S&amp;M growth), adjusted EBITDA loss remained <strong>$59M</strong>, Q1 free cash flow burn was <strong>$71M</strong> and full‑year FCF burn is guided to <strong>$185M–$195M</strong>; the company has ~ <strong>$1.2B</strong> cash but continues to reinvest heavily, which may pressure near‑term profitability.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>第一季度超预期，全年指引上调</strong> — Guardant 第一季度收入为 <strong>3.02 亿美元</strong>（同比增长 48%），超过 <strong>10 亿美元</strong> 的过去 12 个月收入，并将 2026 年指引上调至 <strong>13 亿–13.2 亿美元</strong>，显示出持续的收入增长势头。</li>
<li><strong>Shield 筛查势头和利润率扩张</strong> — Shield 在第一季度产生了 <strong>4200 万美元</strong> 的收入，进行了约 <strong>44,000</strong> 次测试，遵循率超过 90%，全国范围内的 Quest 分销，新批准的 2 管 FDA 套件，与 Manulife 的亚洲推广，以及筛查毛利率从 18% 提升至 56%；2026 年 Shield 指引为 <strong>1.86 亿–1.98 亿美元</strong>（约 23 万–24.5 万次测试）。</li>
<li><strong>肿瘤产品和人工智能平台的吸引力</strong> — 肿瘤收入为 <strong>2.05 亿美元</strong>（增长 36%）；Guardant360 液体检测量增长 30%，Guardant360 组织检测在全转录组升级后加速，Reveal 检测量超过 100%，InfinityAI/SmartApps 推动更深层次的采用；Guardant360 液体仍在 FDA 审查中。</li>
<li><strong>生物制药/数据合作和 CDx 势头</strong> — 生物制药和数据收入为 <strong>5300 万美元</strong>（增长 17%），Guardant 目前支持 26 个地区的 CDx 批准，战略交易（例如，默克、Nuvalent）以及 InfinityAI 真实世界证据正在加强长期商业管道。</li>
<li><strong>运营支出增加和持续现金消耗</strong> — 非 GAAP 运营费用增长 34% 至 <strong>2.68 亿美元</strong>（销售和市场增长），调整后的 EBITDA 亏损保持在 <strong>5900 万美元</strong>，第一季度自由现金流消耗为 <strong>7100 万美元</strong>，全年自由现金流消耗指引为 <strong>1.85 亿–1.95 亿美元</strong>；公司拥有约 <strong>12 亿美元</strong> 现金，但仍在大力再投资，这可能会对短期盈利能力造成压力。</li>
</ul>
</div><h2>Guardant Health Stock Up 0.0%</h2>
<div class="lb-trans"><h2>Guardant Health 股票上涨 0.0%</h2>
</div><p>NASDAQ:GH traded up $0.01 during trading hours on Thursday, reaching $92.26. 2,389,102 shares of the stock were exchanged, compared to its average volume of 2,172,853. The stock has a market capitalization of $12.23 billion, a P/E ratio of -27.87 and a beta of 1.48. The firm has a 50 day simple moving average of $88.93 and a 200-day simple moving average of $96.92. Guardant Health has a 52 week low of $36.36 and a 52 week high of $120.74.</p>
<div class="lb-trans"><p>周四交易时段，纳斯达克：GH 股票上涨 $0.01，达到 $92.26。该股票交易量为 2,389,102 股，而其平均交易量为 2,172,853 股。该公司的市值为 122.3 亿美元，市盈率为-27.87，贝塔值为 1.48。该公司 50 日简单移动平均为$88.93，200 日简单移动平均为$96.92。Guardant Health 的 52 周低点为$36.36，52 周高点为$120.74。</p>
</div><h2>Insider Transactions at Guardant Health</h2>
<div class="lb-trans"><h2>Guardant Health 的内部交易</h2>
</div><ul>
<li>Deciphering Disruption: Inside Cathie Wood's Latest Plays</li>
</ul>
<div class="lb-trans"><ul>
<li>解读颠覆：凯西·伍德最新投资策略</li>
</ul>
</div><p>In other Guardant Health news, Director Musa Tariq sold 348 shares of the business's stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $88.09, for a total transaction of $30,655.32. Following the completion of the sale, the director owned 8,394 shares in the company, valued at $739,427.46. The trade was a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, insider Terilyn J. Monroe sold 3,832 shares of the stock in a transaction on Monday, April 6th. The stock was sold at an average price of $92.68, for a total transaction of $355,149.76. Following the sale, the insider directly owned 20,990 shares in the company, valued at $1,945,353.20. This trade represents a 15.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,596 shares of company stock valued at $775,767 over the last 90 days. Insiders own 6.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Guardant Health 的新闻中，董事穆萨·塔里克于 3 月 18 日（星期三）出售了 348 股公司股票。股票以平均价格$88.09 出售，总交易额为$30,655.32。交易完成后，该董事在公司持有 8,394 股，价值$739,427.46。此次交易使其持股减少了 3.98%。该交易已在提交给证券交易委员会的文件中披露，相关文件可在此链接查看。此外，内部人士特里林·J·门罗于 4 月 6 日（星期一）出售了 3,832 股股票。股票以平均价格$92.68 出售，总交易额为$355,149.76。出售后，该内部人士直接持有公司 20,990 股，价值$1,945,353.20。此次交易使其持股减少了 15.44%。该销售的 SEC 文件提供了更多信息。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去 90 天内，内部人士共出售了价值$775,767 的 8,596 股公司股票。内部人士持有公司 6.10% 的股份。</p>
</div><h2>Institutional Investors Weigh In On Guardant Health</h2>
<div class="lb-trans"><h2>机构投资者对 Guardant Health 的看法</h2>
</div><p>Institutional investors have recently modified their holdings of the business. Parallel Advisors LLC boosted its stake in Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company's stock valued at $36,000 after acquiring an additional 219 shares during the period. EFG International AG acquired a new stake in shares of Guardant Health during the 4th quarter worth approximately $41,000. Kestra Advisory Services LLC acquired a new stake in shares of Guardant Health during the 4th quarter worth approximately $56,000. Itau Unibanco Holding S.A. bought a new stake in shares of Guardant Health in the 4th quarter worth approximately $60,000. Finally, Danske Bank A S acquired a new position in Guardant Health during the 3rd quarter valued at approximately $62,000. Institutional investors own 92.60% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近调整了对该公司的持股。Parallel Advisors LLC 在第四季度将其在 Guardant Health 的持股增加了 164.7%。Parallel Advisors LLC 现在拥有 352 股公司股票，价值$36,000，在此期间又增持了 219 股。EFG International AG 在第四季度获得了 Guardant Health 的新股份，价值约$41,000。Kestra Advisory Services LLC 在第四季度获得了 Guardant Health 的新股份，价值约$56,000。意大利联合银行控股公司在第四季度购买了 Guardant Health 的新股份，价值约$60,000。最后，丹麦银行在第三季度获得了 Guardant Health 的新股份，价值约$62,000。机构投资者持有公司 92.60% 的股份。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>3 Fast-Growing Stocks Analysts See Doubling in Price</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只快速增长的股票，分析师预计价格将翻倍</li>
</ul>
</div><p>A number of analysts have recently issued reports on the company. JPMorgan Chase &amp; Co. lifted their target price on Guardant Health from $120.00 to $130.00 and gave the stock an &#34;overweight&#34; rating in a research report on Friday, February 20th. Stifel Nicolaus raised their price objective on Guardant Health from $120.00 to $130.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, February 20th. Citigroup lifted their price objective on Guardant Health from $135.00 to $150.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, February 20th. Raymond James Financial reaffirmed an &#34;outperform&#34; rating and issued a $129.00 target price on shares of Guardant Health in a research report on Monday, February 23rd. Finally, TD Cowen raised their price target on shares of Guardant Health from $130.00 to $135.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, February 20th. Nineteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $128.63.</p>
<div class="lb-trans"><p>最近，一些分析师对该公司发布了报告。摩根大通将 Guardant Health 的目标价格从 120.00 美元上调至 130.00 美元，并在 2 月 20 日的研究报告中给予该股票 “超配” 评级。Stifel Nicolaus 将 Guardant Health 的目标价格从 120.00 美元上调至 130.00 美元，并在 2 月 20 日的研究报告中给予该公司 “买入” 评级。花旗集团将 Guardant Health 的目标价格从 135.00 美元上调至 150.00 美元，并在 2 月 20 日的报告中给予该股票 “买入” 评级。Raymond James Financial 重申了 “跑赢大盘” 评级，并在 2 月 23 日的研究报告中对 Guardant Health 的股票设定了 129.00 美元的目标价格。最后，TD Cowen 将 Guardant Health 的股票目标价格从 130.00 美元上调至 135.00 美元，并在 2 月 20 日的研究报告中给予该股票 “买入” 评级。十九位研究分析师对该股票给予了 “买入” 评级，一位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 128.63 美元。</p>
</div><p><strong>Read Our Latest Research Report on Guardant Health</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Guardant Health 的最新研究报告</strong></p>
</div><h2>About Guardant Health</h2>
<div class="lb-trans"><h2>关于 Guardant Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.</p>
<div class="lb-trans"><p>Guardant Health, Inc 是一家专注于血液癌症诊断的精准肿瘤学公司。公司成立于 2012 年，总部位于加利福尼亚州红木城，开发非侵入性测试，利用循环肿瘤 DNA (ctDNA) 来分析实体肿瘤患者的基因组变化。Guardant Health 的使命是通过向全球临床医生、制药合作伙伴和研究人员提供可操作的数据，推动癌症护理的发展。</p>
</div><p>The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.</p>
<div class="lb-trans"><p>该公司的旗舰产品 Guardant360 是一种下一代测序 (NGS) 检测，旨在检测 70 多种与癌症相关的基因中的突变、拷贝数变异和特定融合。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Guardant Health</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Guardant Health 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=GH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Guardant Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Guardant Health 吗？</h2>
</div><p>Before you consider Guardant Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Guardant Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Guardant Health 并不在名单上。</p>
</div><p>While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Guardant Health 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Guardant Health (NASDAQ:GH) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Market Beat

Guardant Health

基因改革 ETF - ARK

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

标普生物技术 3 倍做多 - Direxion

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

宏利金融

默克

Nuvalent

Guardant Health（纳斯达克代码：GH）公布季度财报，每股收益比预期高出 0.02 美元